Evidence map›Paper›PMID 31662567›Full record

ArticleIn vivo (Athens, Greece)

Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study.

Hyunkyung Park, Dong-Yeop Shin, Inho Kim, Sang-Kyun Sohn, Youngil Koh, Je-Hwan Lee, Kyoo-Hyung Lee, Dae-Young Kim, Hyeong-Joon Kim, Jae-Sook Ahn and 7 more

Open access · diamondAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Hyunkyung Park *Department of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Dong-Yeop Shin *Department of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Inho Kim *Department of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea ihkimmd@snu.ac.kr sksohn@knu.ac.kr.
Sang-Kyun Sohn *Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea ihkimmd@snu.ac.kr sksohn@knu.ac.kr.
Youngil KohDepartment of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Je-Hwan LeeDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kyoo-Hyung LeeDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Dae-Young KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hyeong-Joon KimDepartment of Internal Medicine, Chonnam National University, Hwasun Hospital, Hwasun, Republic of Korea.
Jae-Sook AhnDepartment of Internal Medicine, Chonnam National University, Hwasun Hospital, Hwasun, Republic of Korea.
Jeong-Ok LeeDepartment of Internal Medicine, Seoul National University, Bundang Hospital, Seongnam, Republic of Korea.
Soo-Mee BangDepartment of Internal Medicine, Seoul National University, Bundang Hospital, Seongnam, Republic of Korea.
June-Won CheongDepartment of Internal Medicine, Yonsei University, Severance Hospital, Seoul, Republic of Korea.
Sang-Gon ParkDepartment of Internal Medicine, Chosun University Hospital, Gwangju, Republic of Korea.
Seonyang ParkDepartment of Internal Medicine, Biomedical Research Institute, Cancer Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
Yoo Jin LeeDepartment of Internal Medicine, Kyungpook National University Hospital, Daegu, Republic of Korea.
Seo-Yeon AhnDepartment of Internal Medicine, Chonnam National University, Hwasun Hospital, Hwasun, Republic of Korea.
Chonnam National University Hwasun Hospital · KRSeoul National University Hospital · KRAsan Medical Center · KRInje University Haeundae Paik Hospital · KRKyungpook National University Hospital · KRSeoul National University Bundang Hospital · KRSNUH SMG-SNU Boramae Medical Center · KRUlsan College · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimDroplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients. PATIENTS AND

methodsBetween May 2013 and November 2014, CML patients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively.

resultsPatients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032).

conclusionWe found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response.

Indexed as

Biomarkers, TumorDNA, NeoplasmPolymerase Chain ReactionAdultAgedAged, 80 and overCombined Modality TherapyFemaleFollow-Up StudiesFusion Proteins, bcr-ablHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedNeoplasm, ResidualPrognosisBiomarkers, TumorDNA, NeoplasmFusion Proteins, bcr-ablChronic myeloid leukemiacomplete molecular responsedroplet digital polymerase chain reactionminimal residual diseasetreatment outcome

Identifiers

PMID31662567
PMCPMC6899155
OpenAlexW2985406174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.